Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
Titel:
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
Auteur:
Boyd, Mark A Amin, Janaki Mallon, Patrick W G Kumarasamy, Nagalingeswaran Lombaard, Johan Wood, Robin Chetchotisakd, Ploenchan Phanuphak, Praphan Mohapi, Lerato Azwa, Iskandar Belloso, Waldo H Molina, Jean-Michel Hoy, Jennifer Moore, Cecilia L Emery, Sean Cooper, David A